However, silencing of ciRS-7 in melanoma cells with high ciRS-7 expression had no effect on cell sensitivity to the BRAF inhibitor dabrafenib and the GPX4 inhibitor RSL3 (1S,3R-RSL-3), suggesting that ciRS-7 levels are only a biomarker of chemotherapy response but not a critical mediator in melanoma [151]. This evidence concerns the gene BRAF and melanoma.